Last reviewed · How we verify

Oral Glycopyrrolate Liquid — Competitive Intelligence Brief

Oral Glycopyrrolate Liquid (Oral Glycopyrrolate Liquid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Respiratory.

phase 3 Anticholinergic Muscarinic acetylcholine receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Oral Glycopyrrolate Liquid (Oral Glycopyrrolate Liquid) — Shionogi. Glycopyrrolate is an anticholinergic medication that works by blocking the action of acetylcholine, a neurotransmitter that stimulates the parasympathetic nervous system, thereby reducing secretions and slowing the heart rate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oral Glycopyrrolate Liquid TARGET Oral Glycopyrrolate Liquid Shionogi phase 3 Anticholinergic Muscarinic acetylcholine receptor
Ecclock SOFPIRONIUM BROMIDE Kaken Pharmaceutical marketed Muscarinic acetylcholine receptor M3 2024-01-01
Yupelri REVEFENACIN Mylan Ireland Ltd marketed Anticholinergic [EPC] Muscarinic acetylcholine receptor M3 2018-01-01
Northera DROXIDOPA Lundbeck Na Ltd marketed Catecholamine Muscarinic acetylcholine receptor M1 2014-01-01
Incruse Ellipta UMECLIDINIUM Glaxo Grp England marketed Anticholinergic Muscarinic acetylcholine receptor M4 2013-01-01
Toviaz FESOTERODINE Pfizer marketed fesoterodine Muscarinic acetylcholine receptor M2 2008-01-01
Toviaz Fesoterodine Fumarate Pfizer marketed fesoterodine Muscarinic acetylcholine receptor M2 2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Glycopyrrolate Liquid — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-glycopyrrolate-liquid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: